1. Volume 9, Issue 12, Pages 1143-1148 (December 2008)
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial 
Prof Jack Cuzick, PhD, Ivana Sestak, PhD, David Cella, PhD, Prof Lesley Fallowfield, PhD 
The Lancet Oncology 
Volume 9, Issue 12, Pages (December 2008)
DOI: /S (08)
Copyright © 2008 Elsevier Ltd Terms and Conditions

2. Figure 1
Breast cancer recurrence according to treatment group and whether joint symptoms (with or without vasomotor symptoms) were reported at the 3-month follow-up visit in women without endocrine symptoms at entry
A=anastrozole. T=tamoxifen.
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

3. Figure 2
Breast cancer recurrence for anastrozole and tamoxifen treatments combined at different follow-up times according to endocrine symptoms reported at the 3-month follow-up visit in women with hormone-receptor-positive tumours and without endocrine symptoms at entry
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions